UnitedHealth Group is expected to report Q3 2026 adjusted earnings of $4.12 per share on revenue of $111.38 billion, while its current stock price of $379.98 remains significantly below the average analyst price target of $462.59. The primary focal point for investors this quarter is the medical care ratio (MCR), which analysts estimate will reach 90.1% for the reporting period.
Market sentiment has recently been pressured by lower-than-expected 2027 Medicare Advantage Star Ratings and expanded regulatory investigations into coverage denial practices. However, management's recent decision to raise full-year 2026 adjusted EPS guidance to a range of $19.50 to $20.00 suggests continued confidence in operational cost-management and the recovery of the Optum health services division.